Results 101 to 110 of about 21,169 (256)
South African Journal of Oncology, 2017 Biochemical failure after radical treatment for prostate cancer occurs in up to 30% – 50% of cases. Localisation of clinical disease is challenging because clinical symptoms often manifest long after the initial rise in prostate-specific antigen.
Irene A. Chidothe, David B. Anderson
doaj +1 more source
Cell-Penetrating Peptides, Electroporation, and Drug Delivery
, 2010 Certain short polycations, such as TAT and oligoarginine, rapidly pass through the plasma membranes of mammalian cells by a mechanism called transduction, as well as by endocytosis and macropinocytosis.
Cahill, Kevin
core +1 more source
Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy [PDF]
, 2015 Prostate cancer (CaP) is the most commonly diagnosed cancer in males. There have been dramatic technical advances in radiotherapy delivery, enabling higher doses of radiotherapy to primary cancer, involved lymph nodes and oligometastases with acceptable ...
Butterworth, K. T. +2 more
core +1 more source
BJU International, EarlyView.Objectives To retrospectively analyse the results of the Prostate Testing for Cancer and Treatment (ProtecT; ClinicalTrials.gov identifier: NCT02044172) trial to establish the association between cribriform‐positive and ‐negative prostate cancer (PCa) and the 15‐year risk of metastasis or death from PCa in patients who underwent radical prostatectomy ...
Nikita Sushentsev +15 more
wiley +1 more source
Journal of Medical Radiation Sciences, 2017 Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high‐binding affinity for the PSMA receptor have
Louise Emmett +5 more
doaj +1 more source
NEMA NU 2-2007 performance characteristics of GE Signa integrated PET/MR for different PET isotopes [PDF]
, 2019 BackgroundFully integrated PET/MR systems are being used frequently in clinical research and routine. National Electrical Manufacturers Association (NEMA) characterization of these systems is generally done with F-18 which is clinically the most relevant
D'Asseler, Yves +5 more
core +1 more source
Guideline of guidelines: pelvic lymph node dissection at time of radical prostatectomy
BJU International, EarlyView.Objective To provide a comprehensive review, analysis and critique of guidelines from various oncological and urological organisations regarding the use pelvic lymph node dissection (PLND) in men undergoing radical prostatectomy (RP) for primary treatment of prostate cancer (PCa).
Jonathon Carll +8 more
wiley +1 more source
European Urology Open ScienceBackground and objectives: The association between prostate-specific antigen (PSA) level and probability of metastatic disease on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has not yet been ...
Wietske I. Luining +15 more
doaj +1 more source
Programmable biomaterials for dynamic and responsive drug delivery [PDF]
, 2016 Biomaterials are continually being designed that enable new methods for interacting dynamically with cell and tissues, in turn unlocking new capabilities in areas ranging from drug delivery to regenerative medicine. In this review, we explore some of the
Almquist, BD, Kiani, MT, Stejskalova, A
core +1 more source
Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
, 2018 Various structural types of prodrugs of 2-phosphonomethylpentanedioic acid were synthesized as GCPII inhibitors. The prodrug with the optimal pharmacokinetic profile was obtained by introducing POC groups on both the phosphonate and α-carboxylate. Thus formed Tris-POC-2-PMPA afforded excellent release of parent 2-PMPA following oral administration in ...
Slusher, B. +5 more
openaire +1 more source